Tri-Institutional TRAC Clinical Science Core

三机构 TRAC 临床科学核心

• 批准号: 10675740
• 负责人: Daniel W Fitzgerald
• 金额: $ 20.54万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-08-01 至 2027-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10675740
• 关键词: 5 year old; Address; Aftercare; Area; Award; Biometry; Center for Translational Science Activities; Child; Childhood; Clinical; Clinical Data; Clinical Investigator; Clinical Management; Clinical Sciences; Clinical Trials Unit; Collaborations; Communities; Complement; DNA; Development; Diagnosis; Faculty; Family; Feces; Fostering; Goals; Growth; Haiti; Infrastructure; Institution; Interdisciplinary Study; Laboratories; Leadership; Medicine; Mentorship; Monitor; Morbidity - disease rate; Mycobacterium tuberculosis; National Institute of Allergy and Infectious Disease; Pathway interactions; Pediatric cohort; Peripheral Blood Mononuclear Cell; Persons; Policies; Positioning Attribute; Procedures; Program Evaluation; Recurrence; Regimen; Research; Research Design; Research Personnel; Resources; Role; Sampling; Science; Secure; Serum; Site; Sputum; Tanzania; Technical Expertise; Time; Training; Translational Research; Tuberculosis; Underrepresented Minority; United States National Institutes of Health; Urine; Whole Blood; Woman; Work; biobank; career development; clinical center; cohort; data management; early phase clinical trial; epidemiology study; experience; global health; human subject protection; innovation; medical schools; member; mortality; multidisciplinary; population based; sample collection; tuberculosis drugs

The Clinical Science Core: The role of the Clinical Science Core in the Tri-Institutional TB Research Advancement Center (Tri-I TRAC) is to provide new investigators (NIs), new to TB (N2TB) investigators and other TRAC investigators access to existing clinical TB research expertise, resources, and infrastructure. The goals of the Clinical Science Core are the same as the overall TRAC and are to increase the number of new investigators in TB and to foster innovative multidisciplinary TB research. The activities of the core will primarily concentrate on our partner site GHESKIO in Port au Prince, Haiti, which is an established NIAID TB clinical trials unit with 39 years of TB research collaboration with the Tri-I partners. We will also support TB research collaborations at Weill Bugando School of Medicine in Mwanza Tanzania which is also an NIAID supported TB research site. The Clinical Science Core will provide mentorship in clinical TB research to new investigators, provide technical expertise in clinical TB research including study design, data management, clinical laboratory, and biostatistics. The core will provide access to TB clinical cohorts and a large well curated biobank of clinical samples from Haiti. Cohorts include families with multiple members with TB and their contacts, longitudinal treatment cohorts with well characterized post-treatment recurrences, early bacteriacidal activity (EBA) TB trials with intensive monitoring of Mtb quantity in sputum, pediatric cohorts with children under 5 years of age with active TB and controls without TB, and a 3,000 person population based community cohorts with incident TB cases. Biobanked samples include whole blood, serum, peripheral blood mononuclear cells, urine, sputum, stool, and host DNA. We also have a biobank of all 14,360 Mtb clinical isolates collected at GHESKIO from all new TB cases diagnosed over ten years with associated demographic and clinical data. NIs, N2TB investigators and others will have access to these resources. NIs who receive a Developmental Project Award will also receive from the Clinical Science Core a complement of mentorship, career development, technical experts and access to clinical cohorts and biobanked samples. This full package for NIs is the Training to Independence Pathway. The goal is to help NIs secure an independent faculty position and their first R01. NIs, N2TB, and experienced investigators may also apply to the Clinical Science Core for more targeted support which includes technical experts and access to cohort and biobanked samples. This is time limited (<6 months) targeted core support to foster new multidisciplinary research. The Clinical Science Core will work synergistically with the other TRAC Cores to achieve our overall TRAC goals to have 25 NIs successfully compete for a TB related NIH R01 and transition to independence and to attract at least 5 N2TB investigators to TB science over 5 years. Half will be women and at least 20% underrepresented minorities. We will also initiate new lines of translational research to address the five NIAID priorities in TB science with the ultimate goal of ending morbidity and mortality from TB world-wide.

临床科学核心：临床科学核心在三机构结核病研究中的作用 Advancement Center（TRI-I TRAC）将提供新的调查人员（NIS），新的TB（N2TB）调查人员和 其他TRAC研究人员可以访问现有的临床结核病研究专业知识，资源和基础设施。这 临床科学核心的目标与整体轨道相同，并且要增加新的数量 结核病研究人员并培养创新的多学科结核病研究。核心的活动将 主要集中于我们在海地Au Prince港的合作伙伴网站，这是一家已建立的NIAID TB 与TRI-I合作伙伴进行了39年结核病研究合作的临床试验部门。我们还将支持结核病 坦桑尼亚Mwanza的Weill Bugando医学院的研究合作也是Niaid 支持的结核病研究网站。临床科学核心将为临床结核病研究提供指导 研究人员，提供临床结核病研究的技术专长，包括研究设计，数据管理， 临床实验室和生物统计学。核心将提供进入结核病临床队列和大井的访问 来自海地的临床样本的策划生物库。队列包括有多个有结核病和多个成员的家庭 他们的接触，纵向治疗队列，具有良好的表征后处理后复发，早期 细菌活性（EBA）结核病试验，对痰中的MTB数量进行密集监测小儿同类 5岁以下的儿童活跃结核病和没有结核病的对照 基于事件结核病案件的社区人群。生物类样品包括全血，血清，周围 血液单核细胞，尿液，痰，粪便和宿主DNA。我们还有14,360 MTB的生物库 从所有新的结核病病例中收集的临床分离株已诊断为十年来的所有新结核病病例 人口统计和临床数据。 NIS，N2TB调查人员和其他人将可以访问这些资源。 nis 获得发展项目奖的人也将从临床科学核心获得 指导，职业发展，技术专家以及获得临床人群和生物库样本的访问。这 NIS的完整包装是对独立途径的培训。目标是帮助NIS确保独立 教师职位和他们的第一个R01。 NIS，N2TB和经验丰富的研究人员也可能适用于临床 科学核心的更多针对性支持，包括技术专家以及获得队列和生物群的访问 样品。这是时间限制（<6个月）的目标核心支持，以促进新的多学科研究。这 临床科学核心将与其他TRAC核心协同合作，以实现我们的整体TRAC目标 拥有25个NIS成功竞争与结核病相关的NIH R01并过渡到独立性并吸引 在5年内，至少有5名N2TB研究人员进入结核病科学。一半是女性，至少20％ 代表性不足的少数民族。我们还将启动新的转化研究线来解决五个 结核病科学的NIAID优先事项的最终目标是结束全球结核病的发病率和死亡率。